The serum-and-glucocorticoid-inducible-kinase-1 (SGK1) is ubiquitously expressed and under genomic control by cell stress, hormones and further mediators. A most powerful stimulator of SGK1 expression is transforming growth factor TGFb1. SGK1 is activated by insulin and growth factors via phosphatidylinositol-3-kinase and the 3-phosphoinositide-dependent kinase PDK1. As shown recently, SGK1 increases the store-operated Ca 2+ entry (SOCE), which is accomplished by the pore-forming ion channel unit Orai. Most recent observations further revealed that SGK1 plays a critical role in the regulation of fertility. SGK1 is up-regulated in the luminal epithelium of women with unexplained infertility but down-regulated in decidualizing stromal cells of patients with recurrent pregnancy loss. The present study explored whether Orai1 is expressed in endometrium and sensitive to regulation by SGK1 and/or TGFb1. To this end, Orai1 protein abundance was determined by western blotting and SOCE by fura-2 fluorescence. As a result, Orai1 was expressed in human endometrium and in human endometrial Ishikawa cells. Orai1 expression and SOCE in Ishikawa cells were increased by transfection with constitutively active S422D SGK1 but not by transfection with inactive K127N SGK1. The difference of SOCE between S422D SGK1 and K127N SGK1-transfected cells was virtually abrogated in the presence of Orai1 inhibitor 2-aminoethoxydiphenyl borate (2-APB, 50 mM). Similar to S422D SGK1 transfection TGFb1 treatment up-regulated both Orai1 protein abundance and SOCE. In conclusion, Orai1 is expressed in the human endometrium and is up-regulated by SGK1 and TGFb1. The present observations thus uncover a novel element in SGK1-sensitive regulation of endometrial cells.
Introduction
The serum and glucocorticoid inducible kinase SGK1 was originally cloned as a gene transcriptionally stimulated by serum and glucocorticoids in rat mammary tumor cells (Firestone et al., 2003) . The human isoform has been discovered as a cell volume-regulated gene (Waldegger et al., 1997) . Expression of SGK1 has been observed in all tissues tested thus far (Waldegger et al., 1997; Kobayashi et al., 1999) . Once expressed, the SGKs are activated by phosphorylation through PI3 kinase and phosphoinositide-dependent kinase PDK1 (Lang et al., 2006) . SGK1 expression is regulated by a wide variety of hormones (Lang et al., 2006) , including gonadropins (Richards et al., 1995; Gonzalez-Robayna et al., 2000; Richards, 2001; Salvador et al., 2001; Chu et al., 2002) , progestin (Feroze-Zaidi et al., 2007) , medroxyprogesterone (Thomas et al., 2004), 1,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ) (Akutsu et al., 2001 ) and interleukin 6 (Meng et al., 2005) . A particularly powerful stimulator of SGK1 expression is transforming growth factor b (TGFb) (Kumar et al., 1999; Waldegger et al., 1999; Lang et al., 2000) , which is strongly expressed and released in the endometrium (Omwandho et al., 2010) . As TGFb3 protein expression is particularly high after menstruation, it has been suggested to participate in the regulation of postmenstrual endometrial regeneration (Omwandho et al., 2010) .
SGK1 is expressed in human endometrium and up-regulated in women with unexplained infertility (Feroze-Zaidi et al., 2007; Salker et al., 2011) . On the other hand, SGK1 is down-regulated in decidualizing stromal cells of patients with recurrent pregnancy loss RPL (Salker et al., 2011) . Little is known, however, about targets of SGK1 in endometrial cells. † Contributed equally and thus share first authorship.
Recent observations revealed SGK1-sensitive regulation of store-operated Ca 2+ entry (SOCE) or Ca 2+ release activated Ca 2+ channel I CRAC (Eylenstein et al., 2011) , a channel composed of the poreforming subunit Orai1, Orai2 or Orai3 (Prakriya et al., 2006; Vig et al., 2006; Yeromin et al., 2006; Putney, 2007; Zhang et al., 2008) and their regulators STIM1 or STIM2 (Zhang et al., 2005; Peinelt et al., 2006; Penna et al., 2008; Fahrner et al., 2009; Smyth et al., 2010) . SGK1 up-regulates SOCE in both mast cells (Eylenstein et al., 2011) and platelets (Borst et al., 2012) . SGK1 counteracts Orai1 degradation by the ubiquitin ligase Nedd4-2 (Eylenstein et al., 2011) and stimulates NF-kB-dependent Orai1 transcription . Cytosolic Ca 2+ activity regulates a variety of fundamental cellular mechanisms including excitation, exocytosis, migration, cell proliferation and cell death (Orrenius et al., 2003; Burgoyne, 2007; Roderick and Cook, 2008; Salter and Watkins, 2009; Becchetti and Arcangeli, 2010) . The present study explored whether Orai1 is expressed in human endometrium and whether its expression and function are sensitive to SGK1. To this end, Orai1 expression was determined in human endometrial tissue and human endometrial Ishikawa cells. Orai1 protein abundance and SOCE were further determined in Ishikawa cells without and with transfection with constitutively active S422D SGK1 or inactive K127N SGK1 as well as without or with prior TGFb1 treatment.
Materials and Methods

Human tissue
Human endometrial tissue was obtained from premenopausal patients (n ¼ 13, age 36.4 + 4.4 years, range 32-43) either by outpatient Pipelle biopsy or at the time of laparoscopic supracervical hysterectomy for benign indications, such as fibroma and bleeding disorders. The patients did not receive hormonal treatment. The phase of the cycle was determined on the basis of last menstrual period and histological dating. For total protein analysis, the freshly obtained endometrial tissue was treated with lysis buffer (50 mM Tris, 150 mM NaCl, 1% Triton X-100, 0.5% Na-deoxycholate, 0.4% b-Mercaptoethanol, Proteinase-Inhibitor Cocktail, Roche, Mannheim, Germany). Protein lysate was applied to a polyacrylamide gel and analyzed by western blot.
Ethical approval
The study was approved by the ethics committees of the University of Tübingen and the NHS National Research Ethics Service (REC reference no. 1997/5056). Written informed consent was obtained from all patients before endometrial sampling.
Cell culture
Ishikawa cells (Jan Brosens, Division of Reproductive Health, Warwick Medical School, Coventry, UK) were cultured in Dulbecco's MEM/F12 with and without phenol red media, containing 10% fetal calf serum (FCS), 1% antibiotic/antimycotic solution and 365 mg/l (2.5 mM) glutamine.
Where indicated, the cells were transiently transfected with the constitutively active SGK1 mutant S422D SGK1 (hSGK1 SD in pIRES-EGFP or in pcDNA 3.1(+)) or the inactive mutant K127N SGK1 (hSGK1 KN in pIRES-EGFP or pcDNA 3.1(+)) (Lang et al., 2000) using FuGENE HD transfection reagent (Roche Diagnostics, Mannheim, Germany) according to the manufacture's instructions.
Where indicated the cells were treated with TGFb1 (biomol, Hamburg, Germany) for 2 or 24 h at concentrations of 0.2, 2, 20, 200 ng/ml (n ¼ 5-6 each), or with Orai 1 inhibitor 2-aminoethoxydiphenyl borate (2-ABP, 50 mM, Sigma-Aldrich, Schnelldorf, Germany) for 30 min prior to measurements (n ¼ 5). In a separate experiment, the cells were treated with TGFb1 in serum-deprived medium (0.5% serum). 
Real-time PCR
Total RNA was extracted from Ishikawa cells in Tri-Fast (Peqlab, Erlangen, Germany) according to the manufacturer's instructions. After DNAse digestion reverse transcription of total RNA was performed using Transcriptor High Fidelity cDNA Synthesis Kit (Roche Diagnostics, Penzberg, Germany). Real-time polymerase chain reaction (RT -PCR) amplification of the respective genes were set up in a total volume of 20 ml using 2 mg of cDNA, 500 nM forward and reverse primers and 2X GoTaq w Mast Mix (Promega, Mannheim, Germany) according to the manufacturer's protocol. Cycling conditions were as follows: initial denaturation at 958C for 2 min, followed by 39 cycles of 958C for 15 s, 588C for 15 s and 688C for 20 s. For the amplification the following primers were used (5 Specificity of PCR products was confirmed by analysis of a melting curve. Real-time PCR amplifications were performed on a CFX96 Real-Time System (Biorad, Munich, Germany) and all experiments were done in duplicate. The house-keeping genes tbp (TATA binding protein) or gapdh were amplified to standardize the amount of sample RNA. Relative quantification of gene expression was achieved using the DCT method as described earlier (Pfaffl, 2001) .
Western blotting
For total protein analysis, freshly isolated tissue or Ishikawa cells 48 h posttransfection with the active or the inactive mutant of SGK1 were harvested with lysis buffer (50 mM Tris, 150 mM NaCl, 1% Triton X-100, 0.5% Na-deoxycholate, 0.4% b-Mercaptoethanol, Proteinase-Inhibitor Cocktail, Roche, Mannheim, Germany Eylenstein et al., 2011) . The appropriate band has been identified by using Orai1 overexpressing cells (Eylenstein et al., 2011; Eylenstein et al., 2012) . Even though SGK1 transcript levels increased already after 2 h, we choose to determine the effect on Orai1 protein abundance 24 h after TGFb administration in order to allow time for SGK1 translation, SGK1 activation, SGK1 dependent phosphorylation 
Statistical analysis
Data are provided as means + SEM; n represents the number of independent experiments. All data were tested for significance using Student's unpaired two-tailed t-test, one sample t-test or ANOVA (Dunnets test), where applicable. Results with P , 0.05 were considered statistically significant.
Results
Endometrial expression of Orai1
In a first series of experiments, western blotting was employed to determine the expression of Orai1 protein in human endometrium and in human endometrial Ishikawa cells. As illustrated in Fig. 1 , Orai1 protein is indeed expressed in both, human endometrium and in human endometrial Ishikawa cells. SGK1 and Orai1 were expressed in both the proliferative and secretory phases. The respective transcript levels relative to the transcript levels of GAPDH were for SGK1 1.00 + 0.19 a.u. (n ¼ 6) in the proliferative phase and 3.19 + 0.82 a.u.
(n ¼ 5) in the secretory phase, and for Orai 1 0.45 + 0.07 a.u. (n ¼ 6) in the proliferative phase and 0.58 + 0.12 a.u. (n ¼ 5) in the secretory phase. The average SGK1 transcript levels were significantly (P , 0.05) higher in the secretory phase than in the proliferative phase. The average Orai1 transcript levels tended to be higher in the secretory phase than in the proliferative phase, a difference, however, not reaching statistical significance. Additional experiments were performed to elucidate whether Orai1 protein expression in Ishikawa cells is sensitive to SGK1. To this end, Ishikawa cells were transfected with either the constitutively active mutant (1 mM) addition in non-transfected Ishikawa cells prior to (white squares) and following a 24 h treatment with 0.2 ng/ml (grey squares) and 2 ng/ml (black squares) TGFb1. (B, C). Arithmetic means (+SEM, n ¼ 8, each experiment 10 -22 cells) of peak (B) and slope (C) increase of fura-2-fluorescence ratio in non-transfected Ishikawa cells prior to (white bars) and following a 24 h treatment with 0.2 ng/ml (grey bars), 2, 20 and 200 ng/ml (black bars) TGFb1. ***(P , 0.001) indicates statistically significant difference to respective value in the absence of TGFb1.
SGK1-sensitive SOCE in Ishikawa cells
SGK1 sensitivity of store-operated Ca 21 entry Fura-2 fluorescence was employed to determine SOCE in Ishikawa cells (Fig. 2) SGK1 (0.42 + 0.04 a.u., n ¼ 6) and following transfection with K127N SGK1 (0.46 + 0.04 a.u., n ¼ 6).
The addition of the store-depleting sarcoendoplasmic reticulum Ca 2+ -ATPase inhibitor thapsigargin (1 mM) triggered release of Ca 2+ from intracellular stores, leading to rapid, transient increase in cytosolic Ca 2+ activity. The increase of intracellular Ca 2+ concentration following thapsigargin treatment was again similar in cells transfected with S422D SGK1 (0.72 + 0.04 a.u., n ¼ 6) and in cells transfected with K127N SGK1 (0.66 + 0.07 a.u., n ¼ 6). In contrast, both, peak and slope of SOCE were significantly higher in cells transfected with S422D SGK1 than in non-transfected cells or in cells transfected with K127N SGK1 (Fig. 2) .
Additional experiments tested whether SGK1 sensitive SOCE was modified by Orai1 inhibitor 2-APB (50 mM). As illustrated in Fig. 2 TGFb1 sensitivity of SGK1 and Orai1 expression as well as store-operated Ca 21 entry
As illustrated in Fig. 3 , SGK1 transcript levels were significantly increased by treatment of Ishikawa cells with TGFb1. Thus, further experiments were performed to elucidate whether Orai1 protein abundance and SOCE are sensitive to TGFb1, a strong stimulator of SGK1 expression. As illustrated in Fig. 4 , a 24 h treatment with TGFb1 (2 ng/ml) was followed by a significant increase of Orai1 protein abundance in Ishikawa cells. The increase of Orai1 protein abundance was paralleled by a similar increase of SOCE (Fig. 5) . In an additional series of experiments, TGFb1 was applied in serumdeprived medium (0.5% FCS). Addition of TGFb1 in serum-deprived medium increased the Orai1 protein abundance significantly (P , 0.001) from 0.28 + 0.02 (n ¼ 12) to 0.42 + 0.03 (n ¼ 10) arbitrary units. The effect of TGFb1 on SOCE was virtually abolished by treatment of the Ishikawa cells with the selective (Ackermann et al., 2011) SGK1 inhibitor EMD638683 (Fig. 6 ).
Discussion
The present study reveals the expression of Orai1 in both, human endometrial tissue and in human endometrial Ishikawa cells. The study further uncovers the up-regulation of Orai1 protein and store-operated Ca 2+ entry (SOCE) in those cells following expression of constitutively active serum and glucocorticoid inducible kinase S422D SGK1. SOCE is inhibited and thus the difference between cells expressing S422D SGK1
and inactive K127N SGK1 abolished by 2-APB (50 mM). We further demonstrate that TGFb1, a strong up-regulator of SGK1 expression (Kumar et al., 1999; Waldegger et al., 1999; Lang et al., 2000) , up-regulates SOCE. SGK1 is highly expressed in a wide variety of tumor cells (Amato et al., 2007; Lang et al., 2010; Murakami et al., 2010; Szmulewitz et al., 2012) but may be down-regulated in others (Lessi et al., 2010) . To the best of our knowledge, SGK1 expression in endometrial tumor cells has never been shown before. As SGK1 stimulates cell proliferation and confers cell survival (Shanmugam et al., 2007; Simon et al., 2007; Dehner et al., 2008; Amato et al., 2009; Fagerli et al., 2011) , it is not an innocent bystander but actively participates in tumor growth (Sherk et al., 2008; Nasir et al., 2009; Lang et al., 2010; Wang et al., 2010) . Orai1 is similarly implicated in the signaling of cell proliferation (Berra-Romani et al., 2008; Baryshnikov et al., 2009; Motiani et al., 2010; Faouzi et al., 2011; Qu et al., 2011) . The up-regulation of Orai by SGK1 may thus contribute to the regulation of tumor cell proliferation and migration. Along those lines, SGK1 activity is stimulated by signaling involving PI3 kinase and phosphoinositide-dependent kinase PDK1 (Lang et al., 2006) , which in turn contribute to the cellular effects of growth factors (Katso et al., 2001; Segal, 2003; Rudd et al., 2009) .
In view of the TGFb1 sensitivity of Orai1 protein abundance and SOCE, it is tempting to speculate that SGK1-sensitive regulation of Orai1 participates in the TGFb-dependent regulation of postmenstrual endometrial regeneration (Omwandho et al., 2010) . Given the decisive role of Orai1 in the regulation of cell proliferation (Berra-Romani et al., 2008; Baryshnikov et al., 2009; Motiani et al., 2010; Faouzi et al., 2011; Qu et al., 2011) , TGFb may foster endometrial regeneration by SGK1-dependent up-regulation of Orai1, which in turn may be decisive for triggering of cell proliferation. Moreover, secreted TGFb may participate in the crosstalk of endometrial cells and the preimplantation embryo (Jones et al., 2006) . In view of TGFb secretion into peritoneal fluid of women suffering from endometriosis TGFb has further been implicated in the establishment and/or maintenance of endometriosis (Omwandho et al., 2010) . Again, the machinery accomplishing cell proliferation in endometriosis may involve SGK1-dependent up-regulation of Orai1.
SGK1 has been shown to participate in a multitude of further physiological and pathophysiological functions including regulation of cell survival (Lang et al., 2006) . Thus, SGK1 may impact on the function of further channels, carriers and signaling molecules in endometrial cells. In any case, SGK1-dependent regulation of endometrial cell function is apparently decisive for normal endothelial function (Feroze-Zaidi et al., 2007; Salker et al., 2011) and by the same token is critically important in the regulation of cell proliferation and development of tumor growth. Future studies will reveal to which extent SGK1 sensitive Orai1 expression and function contributes to or even accounts for the impact of SGK1 on fertility.
In conclusion, Orai1 is expressed in endometrial Ishikawa cells. Both, protein abundance and function of Orai1 are up-regulated by SGK1 and TGFb1, an effect presumably participating in the regulation of endometrial regeneration.
